Evoglip-50

Composition: Sitagliptin 50 mg

Evoglip 50 contains Sitagliptin 50 mg, a DPP-4 inhibitor used to manage Type 2 Diabetes Mellitus. It works by increasing incretin hormone levels, which help regulate insulin release after meals and decrease excess glucose production in the liver. Evoglip 50 helps improve blood glucose control without causing significant weight gain or hypoglycemia when used alone. It is typically prescribed along with diet control and regular physical activity.

Uses:

• Management of Type 2 Diabetes

• Reduction of fasting and post-meal sugar

• Improved HbA1c control

• Suitable for patients intolerant to other medications

Side Effects:

• Headache

• Respiratory infections

• Stomach discomfort

• Joint pain

• Rare: pancreatitis

Other Details:

• Safe for elderly patients

• Can be used alone or with other anti-diabetic medicines

• Kidney function monitoring may be required